Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866440 | 0.92 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1MAPK1GAAALOX15 | |
| SCHEMBL1864578 | 0.92 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1MAPK1PDE7AGAA | |
| SCHEMBL1863262 | 0.90 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1MAPK1PDE7AGAA | |
| SCHEMBL1861383 | 0.89 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1MAPK1PDE7AGAA | |
| SCHEMBL1867946 | 0.89 | ALDH1A1 (0.58) | HSP90AA1HSP90AB1MAPK1PDE7APTK2 | |
| SCHEMBL1861249 | 0.88 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1MAPK1PDE7AGAA | |
| SCHEMBL1866057 | 0.88 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1MAPK1PDE7AGAA | |
| SCHEMBL1863955 | 0.88 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1MAPK1GAAALOX15 | |
| SCHEMBL1866836 | 0.87 | GAA (0.58) | HSP90AA1HSP90AB1GAAALOX15LMNA | |
| SCHEMBL1867832 | 0.86 | GAA (0.52) | HSP90AA1HSP90AB1MAPK1GAAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2015-10-08 | — | — | US | disclosed |
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2015-10-08 | — | — | US | disclosed |
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2015-10-08 | — | — | US | disclosed |
| EP-2118077-B1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2118077-B1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-09-25 | — | — | US | disclosed |
| US-8748424-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748424-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| EP-2118077-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008097640-A2 | TRIAZOLE COMPOUNDS THAT ARE USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS, SUCH AS CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008097640-A2 | TRIAZOLE COMPOUNDS THAT ARE USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS, SUCH AS CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885MAPK1 676/4885 |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885MAPK1 1032/4885 |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885MAPK1 1336/4885 |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885MAPK1 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.